Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK.
Tomas Sjöberg BexeliusJulia C ChisholmBruce OkoyeTom CecilPaola AngeliniSanjeev DayalPublished in: BMJ case reports (2021)
We present the first young paediatric patient with desmoplastic small round cell tumour (DSRCT) treated in UK with hyperthermic intraperitoneal chemotherapy (HIPEC). A 7-year-old girl was diagnosed with abdominal DSRCT with peritoneal and liver metastases. After six cycles of chemotherapy she obtained a partial response, including almost complete resolution of the two liver metastases. It was decided to pursue cytoreductive surgery (CRS) combined with HIPEC, a procedure commonly performed in adults, but seldom in a child. The surgery was macroscopically complete and the HIPEC uncomplicated. She continued treatment without delays, including whole abdomino-pelvic radiotherapy and maintenance chemotherapy (cyclophosphamide/vinorelbine for 12 months). She is currently in complete remission 4 months after end of treatment and 26 months after diagnosis. HIPEC was made possible by successful collaboration between multiple teams. CRS-HIPEC proved to be safe and feasible and could be offered to other children with diagnoses of peritoneal malignancies across the UK.
Keyphrases
- liver metastases
- locally advanced
- minimally invasive
- end stage renal disease
- intensive care unit
- single cell
- rectal cancer
- stem cells
- chronic kidney disease
- cross sectional
- cell therapy
- young adults
- radiation therapy
- squamous cell carcinoma
- ejection fraction
- case report
- systemic lupus erythematosus
- combination therapy
- coronary artery disease
- radiation induced
- single molecule
- peritoneal dialysis
- urinary tract infection